skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.06d (Release date: 2017-06-26)
SearchBox Top
SearchBox Bottom
IDO Inhibitor NLG919 (Code C113793)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: IDO Inhibitor NLG919

Definition: An orally available inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1), with potential immunomodulating and antineoplastic activities. Upon administration, NLG919 targets and binds to IDO1, a cytosolic enzyme responsible for the oxidation of the essential amino acid tryptophan into kynurenine. By inhibiting IDO1 and decreasing kynurenine in tumor cells, this agent increases tryptophan levels, restores the proliferation and activation of various immune cells, including dendritic cells (DCs), natural killer (NK) cells, and T-lymphocytes, and causes a reduction in tumor-associated regulatory T-cells (Tregs). Activation of the immune system, which is suppressed in many cancers, may induce a cytotoxic T-lymphocyte (CTL) response against the IDO1-expressing tumor cells. IDO1 is overexpressed by a variety of tumor cell types and plays an important role in immunosuppression. Tryptophan depletion is associated with immunosuppression caused by T-cell suppression.

Display Name: IDO Inhibitor NLG919

Label: IDO Inhibitor NLG919

NCI Thesaurus Code: C113793 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: CL471774  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
IDO Inhibitor NLG919

External Source Codes: 
PDQ Closed Trial Search ID 757383
PDQ Open Trial Search ID 757383 (check for NCI PDQ open clinical trial info)

Other Properties:
     Name Value (qualifiers indented underneath)
code C113793
Contributing_Source CTRP
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom